Cargando…
IL-24 is the key effector of Th9 cell-mediated tumor immunotherapy
Th9 cells are powerful effector T cells for cancer immunotherapy. However, the underlying antitumor mechanism of Th9 cells still needs to be further elucidated. Here, we show that Th9 cells express high levels of not only IL-9, but also IL-24. We found that knockout of Il24 gene in Th9 cells promote...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10480301/ https://www.ncbi.nlm.nih.gov/pubmed/37680459 http://dx.doi.org/10.1016/j.isci.2023.107531 |
_version_ | 1785101765105942528 |
---|---|
author | Chen, Jintong Zhang, Yunwei Zhang, Hua Zhang, Mingyue Dong, He Qin, Tianxue Gao, Sujun Wang, Siqing |
author_facet | Chen, Jintong Zhang, Yunwei Zhang, Hua Zhang, Mingyue Dong, He Qin, Tianxue Gao, Sujun Wang, Siqing |
author_sort | Chen, Jintong |
collection | PubMed |
description | Th9 cells are powerful effector T cells for cancer immunotherapy. However, the underlying antitumor mechanism of Th9 cells still needs to be further elucidated. Here, we show that Th9 cells express high levels of not only IL-9, but also IL-24. We found that knockout of Il24 gene in Th9 cells promotes Th9 cell proliferation in vitro, but decreases Th9 cell survival in vitro and in vivo. Interestingly, knockout of Il24 gene in Th9 cells decreases the tumor-specific cytotoxicity of Th9 cells in vitro. In addition, immunotherapy with Il24 knockout Th9 cells exhibit less tumor inhibition than regular Th9 cells in mouse tumor models. We found that inhibition of Foxo1 by a specific inhibitor downregulates IL-24 expression in Th9 cells and decreases Th9 cell antitumor efficacy in vivo. Our results identify IL-24 as a powerful antitumor effector of Th9 cells and provide a target in Th9 cell-mediated tumor therapy. |
format | Online Article Text |
id | pubmed-10480301 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-104803012023-09-07 IL-24 is the key effector of Th9 cell-mediated tumor immunotherapy Chen, Jintong Zhang, Yunwei Zhang, Hua Zhang, Mingyue Dong, He Qin, Tianxue Gao, Sujun Wang, Siqing iScience Article Th9 cells are powerful effector T cells for cancer immunotherapy. However, the underlying antitumor mechanism of Th9 cells still needs to be further elucidated. Here, we show that Th9 cells express high levels of not only IL-9, but also IL-24. We found that knockout of Il24 gene in Th9 cells promotes Th9 cell proliferation in vitro, but decreases Th9 cell survival in vitro and in vivo. Interestingly, knockout of Il24 gene in Th9 cells decreases the tumor-specific cytotoxicity of Th9 cells in vitro. In addition, immunotherapy with Il24 knockout Th9 cells exhibit less tumor inhibition than regular Th9 cells in mouse tumor models. We found that inhibition of Foxo1 by a specific inhibitor downregulates IL-24 expression in Th9 cells and decreases Th9 cell antitumor efficacy in vivo. Our results identify IL-24 as a powerful antitumor effector of Th9 cells and provide a target in Th9 cell-mediated tumor therapy. Elsevier 2023-08-03 /pmc/articles/PMC10480301/ /pubmed/37680459 http://dx.doi.org/10.1016/j.isci.2023.107531 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Article Chen, Jintong Zhang, Yunwei Zhang, Hua Zhang, Mingyue Dong, He Qin, Tianxue Gao, Sujun Wang, Siqing IL-24 is the key effector of Th9 cell-mediated tumor immunotherapy |
title | IL-24 is the key effector of Th9 cell-mediated tumor immunotherapy |
title_full | IL-24 is the key effector of Th9 cell-mediated tumor immunotherapy |
title_fullStr | IL-24 is the key effector of Th9 cell-mediated tumor immunotherapy |
title_full_unstemmed | IL-24 is the key effector of Th9 cell-mediated tumor immunotherapy |
title_short | IL-24 is the key effector of Th9 cell-mediated tumor immunotherapy |
title_sort | il-24 is the key effector of th9 cell-mediated tumor immunotherapy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10480301/ https://www.ncbi.nlm.nih.gov/pubmed/37680459 http://dx.doi.org/10.1016/j.isci.2023.107531 |
work_keys_str_mv | AT chenjintong il24isthekeyeffectorofth9cellmediatedtumorimmunotherapy AT zhangyunwei il24isthekeyeffectorofth9cellmediatedtumorimmunotherapy AT zhanghua il24isthekeyeffectorofth9cellmediatedtumorimmunotherapy AT zhangmingyue il24isthekeyeffectorofth9cellmediatedtumorimmunotherapy AT donghe il24isthekeyeffectorofth9cellmediatedtumorimmunotherapy AT qintianxue il24isthekeyeffectorofth9cellmediatedtumorimmunotherapy AT gaosujun il24isthekeyeffectorofth9cellmediatedtumorimmunotherapy AT wangsiqing il24isthekeyeffectorofth9cellmediatedtumorimmunotherapy |